Drugs / VIMEKOFUSP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04224857 | Apr 2019 → Apr 2020 | ulcerative colitis | Applied Molecular Transport | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04741087 Comparator | Feb 2021 → Mar 2022 | pouchitis | Applied Molecular Transport | Completed | No outcome recorded |
| Phase 2 | NCT05372939 Comparator | Feb 2021 → Jun 2022 | ulcerative colitis | Applied Molecular Transport | Completed | No outcome recorded |
| Phase 2 | NCT04583358 Comparator | Aug 2020 → Nov 2022 | ulcerative colitis | Applied Molecular Transport | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIMEKOFUSP | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314977 ↗ |
| Known as | AMT 101 | “AMT 101 is orally administered biological therapeutic taken once daily” NCT05372939 ↗5“AMT 101 is orally administered biological therapeutic taken once daily” NCT04583358 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL5314977 ↗ |
| Route | Oral | “Oral AMT-101” NCT04224857 ↗ |